



SZABO SCANDIC

Part of Europa Biosite

Produktinformation



Forschungsprodukte & Biochemikalien



Zellkultur & Verbrauchsmaterial



Diagnostik & molekulare Diagnostik



Laborgeräte & Service

Weitere Information auf den folgenden Seiten!
See the following pages for more information!



Lieferung & Zahlungsart

siehe unsere [Liefer- und Versandbedingungen](#)

Zuschläge

- Mindermengenzuschlag
- Trockeneiszuschlag
- Gefahrgutzuschlag
- Expressversand

SZABO-SCANDIC HandelsgmbH

Quellenstraße 110, A-1100 Wien

T. +43(0)1 489 3961-0

F. +43(0)1 489 3961-7

mail@szabo-scandic.com

www.szabo-scandic.com

[linkedin.com/company/szaboscandic](https://www.linkedin.com/company/szaboscandic) 

PRODUCT INFORMATION



Pirtobrutinib

Item No. 36775

CAS Registry No.: 2101700-15-4
Formal Name: 5-amino-3-[4-[[[5-fluoro-2-methoxybenzoyl]amino]methyl]phenyl]-1-[(1S)-2,2,2-trifluoro-1-methylethyl]-1H-pyrazole-4-carboxamide

Synonyms: LOXO-305, LY3527727

MF: C₂₂H₂₁F₄N₅O₃

FW: 479.4


Purity: ≥98%

UV/Vis.: λ_{max}: 234 nm

Supplied as: A solid

Storage: -20°C

Stability: ≥4 years



Information represents the product specifications. Batch specific analytical results are provided on each certificate of analysis.

Laboratory Procedures

Pirtobrutinib is supplied as a solid. A stock solution may be made by dissolving the pirtobrutinib in the solvent of choice, which should be purged with an inert gas. Pirtobrutinib is soluble in organic solvents such as ethanol, DMSO, and dimethyl formamide (DMF). The solubility of Pirtobrutinib in ethanol and DMSO is approximately 5 mg/ml and approximately 3 mg/ml in DMF.

Description

Pirtobrutinib is an inhibitor of Bruton's tyrosine kinase (BTK).¹ It inhibits wild-type and mutant BTK (IC₅₀s = 10-100 and <10 nM for wild-type BTK and BTK^{C481S}, respectively). It is selective for BTK over EGFR (IC₅₀ = 1-10 μM). Pirtobrutinib decreases the number of Ki67-positive cells, a marker of cell proliferation, in MEC-1 chronic lymphocytic leukemia (CLL) mouse xenograft models using MEC-1 cells that express either wild-type BTK or BTK^{C481S}.²

References

1. Guisot, N. Compounds useful as kinase inhibitors. **WO 2017/103611** (2017).
2. Aslan, B., Kismali, G., Iles, L.R., *et al.* Pirtobrutinib inhibits wild-type and mutant Bruton's tyrosine kinase-mediated signaling in chronic lymphocytic leukemia. *Blood Cancer J.* **12**(5), 80 (2022).

WARNING

THIS PRODUCT IS FOR RESEARCH ONLY - NOT FOR HUMAN OR VETERINARY DIAGNOSTIC OR THERAPEUTIC USE.

SAFETY DATA

This material should be considered hazardous until further information becomes available. Do not ingest, inhale, get in eyes, on skin, or on clothing. Wash thoroughly after handling. Before use, the user must review the [complete](#) Safety Data Sheet, which has been sent via email to your institution.

WARRANTY AND LIMITATION OF REMEDY

Buyer agrees to purchase the material subject to Cayman's Terms and Conditions. Complete Terms and Conditions including Warranty and Limitation of Liability information can be found on our website.

Copyright Cayman Chemical Company, 12/21/2022

CAYMAN CHEMICAL

1180 EAST ELLSWORTH RD
ANN ARBOR, MI 48108 · USA

PHONE: [800] 364-9897

[734] 971-3335

FAX: [734] 971-3640

CUSTSERV@CAYMANCHEM.COM

WWW.CAYMANCHEM.COM